In brief
- The U.S. Drug Enforcement Administration (DEA) has announced its intention to place 7-hydroxymitragynine (7-OH), a kratom alkaloid, into Schedule I, but only above a specific concentration.
- The threshold is 0.050% by dry weight, or more than 1.00 milligram per product: kratom leaf, where 7-OH appears in minimal amounts, falls below this limit and remains outside the measure.
- This is a temporary scheduling for up to two years, renewable; the notice was published on July 6, 2026, and the order cannot be issued before August 5.
On July 6, the DEA published a notice of intent in the U.S. Federal Register to temporarily control 7-hydroxymitragynine, one of the alkaloids found in Mitragyna speciosa, or kratom. The novelty lies not in the substance itself, but in how the regulation is drafted: for the first time, control is defined by a concentration threshold, distinguishing between traditional leaf and the ultra-concentrated extracts that have proliferated in convenience stores across the country.
Where exactly the line is drawn
The text establishes three criteria. For botanical material, any product containing more than 0.050% 7-OH by dry weight would be controlled. For products obtained through synthesis or subsequent processing—extracts, concentrates, edibles, or tablets—the limit is the same 0.050% weight/weight, weight/volume, or volume/volume, or more than 1.00 milligram of 7-OH in the product. The scope also includes isomers, esters, ethers, and salts of the compound. The DEA itself acknowledges in the document that in unprocessed plants, 7-OH represents less than two percent of the total alkaloid content or appears only in trace amounts, well below the threshold: mitragynine, the leaf’s primary alkaloid, is not included in the measure.
Data used by the agency
The notice is supported by a scientific evaluation submitted by the Department of Health and Human Services (HHS) and data from U.S. poison control centers, which only began registering 7-OH with specific codes between February and May 2025. In that initial monitoring period, 53 inquiries were recorded; between January 1 and July 31, 2025, the figure rose to 165 exposure cases. Of those involving only 7-OH, 35% resulted in serious health issues, and 67% required treatment at a healthcare facility. The agency emphasizes that 7-OH has opioid activity comparable to classical opioids, with risks of tolerance, dependence, and respiratory depression, and that there are no controlled clinical trials establishing safe doses for these concentrates. It is worth noting that 7-OH is also an active metabolite of mitragynine in the body, which complicates the interpretation of some exposure data.
What it implies
The most interesting aspect of the text is the methodology: recognizing that dose and concentration completely change a substance’s profile, rather than treating an infused leaf and a highly potent extract the same way. That distinction is precisely the principle of harm reduction: knowing what is being consumed and in what quantity. The known downside of any molecule-based control is the market shift toward analogs that are not yet listed and about which even less toxicological information exists. For those who already use kratom, the underlying practical problem remains the same before and after the regulation: the enormous variability in concentration between products sold without reliable labeling or independent analysis. Furthermore, this is a temporary and reviewable scheduling, not a definitive decision regarding the plant itself.
Source
- Drug Enforcement Administration. Schedules of Controlled Substance: Temporary Placement of 7-Hydroxymitragynine Above a Specified Threshold in Schedule I. Federal Register, July 6, 2026.
Educational content written from a harm reduction perspective and with respect for individual freedom. It is not a substitute for advice from a healthcare professional and is not intended to encourage or condemn any drug use.
